Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
By E. Van Cutsem, C. Twelves, J. Cassidy, D. Allman, E. Bajetta, M. Boyer, R. Bugat, M. Findlay, S. Frings, M. Jahn and 11 more. Journal of Clinical Oncology, 2001
1,055 citations recorded by the source corpus.
Subfields: Dermatology, Oncology
View Paper: https://www.semanticscholar.org/paper/dcac7c4142e0d071ee323396dedaa9e2c74dbc26
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- [Systemic therapy for colorectal cancer]. (2005, background): “These two randomized trials, and others with oral fluoropyrimidines, suggest that UFT/LV and capecitabine provide an equally effective, but safer, oral alternative to the standard intravenous bolus 5FU/LV regimen for metastatic colorectal cancer (38,39).”
- Hypokalemia secondary to capecitabine: a hidden toxicity? (2007, neutral): “All rights reserved 177 O R I G I N A L R E S E A R C H”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient ”
- Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. (2008, methodology): “The noninferiority margin of 1.23 corresponds to retention of at least 50% of the benefit that oxaliplatin plus FU/FA has shown over FU/FA alone in the first-line treatment of MCRC.”